Anti-CD27 antibody (160-260) [PT1818] (STJA0006232)

SKU:
STJA0006232

Current Stock:
Host: Mouse
Applications: WB/ELISA
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-CD27 antigen (160-260) is suitable for use in Western Blot and ELISA research applications.
Clonality: Monoclonal
Clone ID: PT1818
Conjugation: Unconjugated
Isotype: IgG2bk
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: CD27
Gene ID: 939
Uniprot ID: CD27_HUMAN
Immunogen Region: 160-260
Specificity: This antibody detects endogenous levels of CD27 at Human, Predict react with Mouse
Immunogen: Synthesized peptide derived from human CD27 AA range: 160-260
Tissue Specificity Found in most T-lymphocytes.
Post Translational Modifications Phosphorylated. O-glycosylated with core 1 or possibly core 8 glycans.
Function Receptor for CD70/CD27L. May play a role in survival of activated T-cells. May play a role in apoptosis through association with SIVA1.
Protein Name Cd27 Antigen
Cd27l Receptor
T-Cell Activation Antigen Cd27
T14
Tumor Necrosis Factor Receptor Superfamily Member 7
Cd Antigen Cd27
Database Links Reactome: R-HSA-5669034
Cellular Localisation Membrane
Single-Pass Type I Membrane Protein
Alternative Antibody Names Anti-Cd27 Antigen antibody
Anti-Cd27l Receptor antibody
Anti-T-Cell Activation Antigen Cd27 antibody
Anti-T14 antibody
Anti-Tumor Necrosis Factor Receptor Superfamily Member 7 antibody
Anti-Cd Antigen Cd27 antibody
Anti-CD27 antibody
Anti-TNFRSF7 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance